<SEC-DOCUMENT>0000724910-24-000004.txt : 20240617
<SEC-HEADER>0000724910-24-000004.hdr.sgml : 20240617
<ACCEPTANCE-DATETIME>20240617162444
ACCESSION NUMBER:		0000724910-24-000004
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20240617
DATE AS OF CHANGE:		20240617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NVE CORP /NEW/
		CENTRAL INDEX KEY:			0000724910
		STANDARD INDUSTRIAL CLASSIFICATION:	SEMICONDUCTORS & RELATED DEVICES [3674]
		ORGANIZATION NAME:           	04 Manufacturing
		IRS NUMBER:				411424202
		STATE OF INCORPORATION:			MN
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-12196
		FILM NUMBER:		241048612

	BUSINESS ADDRESS:	
		STREET 1:		11409 VALLEY VIEW ROAD
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		9528299217

	MAIL ADDRESS:	
		STREET 1:		11409 VALLEY VIEW ROAD
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PREMIS CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>NVE_2024_Letter.htm
<DESCRIPTION>SHAREHOLDER LETTER
<TEXT>
<html>
<font style="font-size: 10pt; font-family: Times New Roman;">&nbsp;<br></font>
<hr style="margin-top: -5px; color: black;" noshade size="3">
<hr style="margin-top: -14px; color: black;" noshade size="1">
<div align="center"><font style="font-size: 5pt; font-family: Times New Roman;">&nbsp;<br></font>
<b><font face="Times New Roman" style="font-size:12pt;">UNITED
STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br>
</font></b><font style="font-size: 10pt; font-family: Times New Roman;"><b>Washington,
D.C.&nbsp;&nbsp;20549<br>
</b></font><font style="font-size: 10pt; font-family: Times New Roman; line-height: 5pt;">_______________</font></div>
<p align="center"><b><font size="5" face="Times New Roman" style="font-size:12pt;">SCHEDULE
14A INFORMATION</font></b></p>
<div align="center"><font face="Times New Roman" style="font-size:10pt;"> Proxy
Statement Pursuant to Section&nbsp;14(a)&nbsp;of the Securities Exchange Act of
1934<br>
(Amendment No.&nbsp;&nbsp;&nbsp;)<br>
</font></div>
<font face="Times New Roman" style="font-size:10pt;">Filed by the Registrant&nbsp;&nbsp;&#x2611;<br>
<div align="CENTER"></div>
Filed by a party other than the Registrant&nbsp;&nbsp;&#x2610;<br>
&nbsp; <br>
Check the appropriate box:</font>
<table style="font-size: 10pt; font-family: Times New Roman;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td width="18">&#x2610;</td>
<td>Preliminary Proxy Statement</td>
</tr>
<tr>
<td>&#x2610;</td>
<td>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</td>
</tr>
<tr>
<td>&#x2610;</td>
<td>Definitive Proxy Statement</td>
</tr>
<tr>
<td>&#x2611;</td>
<td>Definitive Additional Materials</td>
</tr>
<tr>
<td>&#x2610;</td>
<td>Soliciting Material under &sect; 240.14a-12</td>
</tr>
</table>
<b><font face="Times New Roman" style="font-size:10pt;font-weight:bold;">&nbsp;</font></b>
<div align="center"><img src="nve-logo.gif" width="276" height="54" alt="NVE Logo"><font style="display: inline; font-size: 26pt; font-family: Arial;"><b><br>
NVE Corporation</b><br>
</font><font face="Times New Roman" style="font-size:10pt;">(Name of Registrant
as Specified In Its Charter)<br>
&nbsp;<br>
&nbsp;<br>
(Name of Person(s)&nbsp;Filing Proxy Statement, if other than the Registrant)<br>
&nbsp;<br>
</font></div>
<table style="font-size: 10pt; font-family: Times New Roman;" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td colspan="3" valign="top">Payment of Filing Fee (Check all boxes that apply):</td>
</tr>
<tr>
<td width="18" valign="top">&#x2611;</td>
<td colspan="2" valign="top">No fee required.</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&#x2610;</td>
<td colspan="2" valign="top">Fee paid previously with preliminary materials.</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&#x2610;</td>
<td colspan="2" valign="top"> Fee computed on table in exhibit required by Item
25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
<tr>
<td valign="top">&nbsp;</td>
<td colspan="2" valign="top">&nbsp;</td>
</tr>
</table><hr style="margin-top: -5px; color: black;" noshade size="1">
<hr style="margin-top: -15px; color: black;" noshade size="3">
<div style="page-break-after: always;"><font face="Times New Roman, Times, serif" size="2">&nbsp;</font><br>
</div>
<hr color="#0046AD" noshade>
<table width="100%" border="0" cellspacing="00" cellpadding="0">
<tr>
<td><img src="sml-logo.gif" width="126" height="35" alt="Small NVE logo"></td>
<td>
<div align="right"><font face="Arial, Helvetica" style="font-size:8pt;">11409 Valley View Road<br>Eden Prairie, MN 55344-3617
<br>www.nve.com</font></div></td></tr></table>
<hr color="#0046AD" noshade>
<font style="font-size: 10pt" face="Arial, Helvetica, sans-serif">&nbsp;<br>
<b>Fellow Shareholders,</b></font><font style="font-size: 10pt" font-family: Times New Roman;"><br>
We continued our strong earnings and above-market shareholder returns the past
year. We continued to develop
innovative products and invest in R&amp;D, and we began expanding our capabilities.<br>
<br>
<b>Strong Earnings</b><br>
High-value products allowed us to weather an industry downturn the past fiscal
year. We were pleased to report strong earnings and exceptional operating and
net income margins for fiscal 2024 despite a decrease in revenue from a record-shattering
previous year. The industry is recovering and we continue to develop innovative
products, which bode well for the future.<br>
<br>
<b> Product Innovation</b><br>
Our products acquire and transmit information and power. We develop technologies
for high-value market opportunities such as the industrial internet of things
and medical devices. Past year product innovations included:<br>
</font>
<table style="font-size: 10pt; font-family: Times New Roman" border="0" cellspacing="00" cellpadding="0">
<tr>
<td width="18">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td width="1" valign="top">&#149;&nbsp;&nbsp;</td>
<td>Network transceivers and data couplers that operate in harsh environments.<br>
<font style="font-size: 5pt" font-family: Times New Roman;">&nbsp;</font></td>
</tr>
</table>
<table style="font-size: 10pt; font-family: Times New Roman" border="0" cellspacing="00" cellpadding="0">
<tr>
<td width="18">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td valign="top">&#149;&nbsp;&nbsp;</td>
<td>More products combining data couplers with isolated DC-to-DC convertors to
transmit power as well as data.<br>
<font style="font-size: 5pt" font-family: Times New Roman;">&nbsp;</font></td>
</tr>
</table>
<table style="font-size: 10pt; font-family: Times New Roman" border="0" cellspacing="00" cellpadding="0">
<tr>
<td width="18">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td valign="top">&#149;&nbsp;&nbsp;</td>
<td>New product evaluation and demonstration kits to allow customers to easily
visualize and implement compelling
solutions with our unique products.<br>
<font style="font-size: 5pt" font-family: Times New Roman;">&nbsp;</font></td>
</tr>
<tr>
<td width="18">&nbsp;</td>
<td valign="top">&#149; </td>
<td>We earned &#147;CE&#148; markings for our line of the world&#146;s smallest
DC-to-DC convertors.</td>
</tr>
</table>
<font style="font-size: 10pt" font-family: Times New Roman;">&nbsp;<br>
Please visit our website or <i>YouTube</i> channel for more information and demonstrations
of these unique products.<br>
<br>
<b>R&D for the Future</b><br>
We invested in advanced R&D initiatives we expect will drive future growth. Medium-term
product development programs the past year included next-generation MRAM for antitamper
applications, next-generation sensors for medical devices, extremely sensitive
TMR sensors, and wafer-level, chip-scale packaged sensors. Long-term programs
included technology that could provide the energy efficiency needed to accelerate
the use of spintronics in memory, logic, and neuromorphic computing. Some of this
research was published in the past year.<br>
<br>
<b>Aggressive Expansion</b><br>
We are beginning a multimillion-dollar expansion over the next two years. The
investments will increase our capacity and capabilities, including wafer-level
chip-scale manufacturing. Wafer-level chip-scale parts will be smaller and will
allow us to be more self-sufficient and capture more value. We plan to begin production
this fiscal year. <br>
<br>
<b>Other Highlights</b><br>
We extended our partnering agreement with Abbott Laboratories to provide medical
device components, and we are proud to partner with Abbott on life-changing devices
that demand impeccable quality. We have increased product promotion with more
tradeshows, newsletters, and demonstration videos. We continued to pay generous
dividends to enhance your shareholder value, returning $19.3 million in the past
fiscal year. As reported in the accompanying proxy statement, our Total Shareholder
Return for the past three fiscal years was 46%. <br>
<br>
<b>A New Director</b><br>
Sadly, Richard W. Kramp passed away in May 2024. We appreciated his dedicated
service for the past ten years and mourn his loss. We are pleased to welcome Dr.
Kelly Wei to our Board of Directors. Her strong medical device background and
senior executive experience make her exceptionally well-qualified. Dr. Wei looks
forward to meeting shareholders at our upcoming annual meeting. <br>
<br>
<b> A Bright Future</b><br>
Our valued customers, our dedicated employees, and our culture of ingenuity set
the stage for growth and continued success. Thank you for your support.<br>
<br>
Sincerely,<br>
&nbsp;<br>
<img src="dab-sig.gif" alt="-s- Daniel A. Baker" width="115" height="36" border="0"><br>
Daniel A. Baker<br>
President and Chief Executive Officer<br>
&nbsp;<br>
<i><b>Statements in this letter that relate to future plans, events, or performance
are forward-looking statements that are subject to certain risks and uncertainties
including the risk factors listed from time to time in our filings with the SEC,
including our Annual Report on Form 10-K and other reports filed with the SEC.
Actual results could differ materially from the information provided, and we undertake
no obligation to update forward-looking statements.</b></i></font> </html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>nve-logo.gif
<DESCRIPTION>NVE LOGO
<TEXT>
begin 644 nve-logo.gif
M1TE&.#EA% $V +,   !&K0DW>0<C3$!.8GAY>O___^+BXK2TM
M                     "P     % $V   $_[#(20M!..M3NY>7I@E<-8CB
M\*UL@:*5(<QT;=]X?I?4\?[ H'!(+!I?O,\ P&PV X36BN"L"@P=0J#J%$B_
MH"V7>:T<Q..T>MW%5K3LN'Q.K]NY999@G0=/EFE>'6=J?7X>,FH!*F]WCET>
M5(^3E)5W@BN$BE&'$GMIC#&?8P%)G11P@6X4@)9TH:RNLK.SL)%H@:>:7% ?
MH[R<IQ2):;T=O[3%P13(R<[/FRVMA:92J;S5$M-<ML+7>*L3Q-#8@[CDZ.2E
M+<UCRU_;;1^2H,+#[4SKYNE6X6'\ )\9ZC".CS]VA::<@V1/V\(FW4 $;(()
MU<2+LBIZV+7&V)>"5?_>]7A(YJ"? _@ D%"",6(\C##K1+0X1R,+CDX\>DBI
M3]C+?#,+I 1PQ$BVHDB3*ETJ)%NLFDZSD.RY<XU(,"@+F2P LDK0AF##BAU+
M]EB=JQY^JI2VYJN>:!]PYHQ:MJ[=NWBY#@7W):5;>F/<QB6I<JL%@WD3*U[<
M4&Y'M/?40);@F,RIKD\FJUW+N+/GSR8N2:FL$Q%/NK>TOI4,NK7KQ)L#H09<
MA:HO1:A%X;Y)V/;KW\"%[:W'0JW-M%8/?;/28KF\X-"C?ZG,9F %OU]H>_6#
MF<QL/M+#BY=:C"?D[@ F3W!.T0][ (ND#!4\OOYGXP,('Z<\53W_A!^E9)W_
M;LK89R!T J+GFT2J!+B;%/D5V )U QYHX6+HJ;#93,;Y8=YH"5JCWX4D?D9=
M%!2:A!T8F_FG5FDL%<*4")/-:..-./[P73$E?&@&8?ZMU]:$^AG&3$#G#1?3
MDK6I9YP;[W&&RE2Y34 A0A*V@!XM"_['Y)=Q=#F!@.*<UDB#8*!7H04C3D<8
M+6M&">:<^Y6I!BS:.6%+AX>8:1HU8.0I4'%S%DI<)OWU$*($&7;R(EI1TJ<-
MDJL9:BD3Z@D*GRD^%G!B)YJF]Z=L'@($HYV76GKJ4V,,%"4F[XDY#V$1Q1HD
MHTI:LB9UJ<*T4J5X$.3GDYU<26"K1OX(4)V']6HH_[.> ID:<61VHJ8_$9)R
M*X.!Y%ACCN"&N]1LB0Z28*.G^$G9HBP.6>*[BKWHE'F?GO(HJ\!T,M2V\/;;
M)X ;Z:>IK%,DMR[ ::KK[\)AH3LJ*>P>0ETH E8YI6H,9]R8M H5@K#$;4Y\
M2JC0:FSRK#RRL.6=#9U;L;WNGBPS/!BO$%L:_(;&8ZR27F?PS$"O4"UO=A!,
MJ&018]6;Q4%G[/ **_-ESZOE@EIDTUB/Q)J(=91,=#$U'[*9UUDS/'"54>L)
M5MI-VC-?V6432S,=.9ME!]G"_@QWT$./]N9<8=U<&]/*%B,N H@<KOCB01#)
M<JERK!FH'3V3-]%Q@CN[;)!S56?WMV5AR6D%X3I/=%6NFJ>3Z8,)RU'Y8'/$
MU_)%,+*=NCKJ)0UAF'57%7FR*J/NBF^\WLZ/K&KJ\K?1?<FQJM(7'2>Z\>A
M6Z^^U0$_=_9@A?J,2]0S^5?G[KV)=W.\!X[1Z>$OZ23KAVSY.J+<@R6\);7?
<W_[PN0-QO@E!Z%WBFM(PQNEH$ 9,H %1$P$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sml-logo.gif
<DESCRIPTION>SMALL NVE LOGO
<TEXT>
begin 644 sml-logo.gif
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MP0.=J_S+O#OSO42O_B=^+=4H3XJEB1(W[;T]<\(#"NH6Z)4[_>1WMR?^&=>
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<A2=TP-80,)$81NB #PPX80-&",/][+ \ 0$ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>dab-sig.gif
<DESCRIPTION>DANIEL A. BAKER SIGNATURE
<TEXT>
begin 644 dab-sig.gif
M1TE&.#EA<P D +,   $! 0L+"Q<7%R<G)S<W-T]/3V=G9W=W=X>'AYB8F*^O
MK\?'Q]W=W?#P\/____O[^RP     <P D   (_@ ="!Q(L*!!@0P4(%B8H,'!
MAQ C2IQ(L:+%@@T2% @ 0 "! @0 !&!PL:3)DR@E-C@@ $"!!"0',A!@(.5
MAS8?,C 0,Z?%E0$$'.A9$&1. P1\&FS0<H%2B@T0!""@X$'$ @)L,N@H,<$
M!1<+  ! %"*#!"D?)!#PU6K$!@%JICP ("G$!6,%X)R(=ZQ;B5)1,B @(,$#
M! 4D&B";DJE+B(['.IWXX&.! 17%[K6(P*7#K6 A*@ @%^5B  @@+@X)8'+7
MU@,.4'S \2]4L0C<)@A@N^#, 9M+XN7HNB!> G1;\YV*M_A= G8K,A@@H'B!
MQ \;$ C@_&*# =!Y_A^LW!HZXX@S6QO 3-&  NP4%P@00)1!@- &'XC%?]+
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<DM?FH\NGO 67* 'F4XP5-U\:\Y@IX=<# @( .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
